États-Unis · Plateformes & données · MarketWatch

Investors are underestimating AI. But the real challenge is diversification, this strategist says.

Publié par MarketWatch · États-Unis il y a 2 h

Résumé détaillé

Artificial intelligence is all everyone has talked about since the arrival of ChatGPT, but HSBC’s global chief investment officer thinks investors are still underestimating it.

Lire l'article complet sur MarketWatch Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketwatch.com)

Investors are underestimating AI. But the real challenge is diversification, this strategist says.

Résumé détaillé

À lire aussi

Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near

Fortress Biotech GAAP EPS of -$0.23 beats by $0.04, revenue of $19.16M misses by $2.41M

What Is Going on With Micron Stock on Friday?

How Much Is Nvidia Stock Worth Without Jensen Huang?

Earnings call transcript: Zetwerk lifts margins in Q2 2027 as growth stays strong

Novo Nordisk Seeks FDA, EMA Approval For Sickle Cell Disease Treatment – Here Are The Key Takeaways

Investors are underestimating AI. But the real challenge is diversification, this strategist says.

Résumé détaillé

Partager

À lire aussi

Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near

Fortress Biotech GAAP EPS of -$0.23 beats by $0.04, revenue of $19.16M misses by $2.41M

What Is Going on With Micron Stock on Friday?

How Much Is Nvidia Stock Worth Without Jensen Huang?

Earnings call transcript: Zetwerk lifts margins in Q2 2027 as growth stays strong

Novo Nordisk Seeks FDA, EMA Approval For Sickle Cell Disease Treatment – Here Are The Key Takeaways